Logo Image
News
OncClubAll Oncology NewsClinical Trials in Focus
Media
InsightsMedNews WeekOncChatsOncLive News Network®OncLive TVPeer ExchangePodcastsRapid ReadoutsShorts
Conferences
Conference CoverageConference Listing
Events
Giants of Cancer CareCME/CEScientific InterchangesState of the Science Summit / IPCNational Fellows ForumWebinars
More
Partners
Publications
All PublicationsSupplements
Resources
Consensus ViewpointsOncLive AppInteractive ToolsSponsored
Biomarker Consortium

Subscribe

  • News
  • Media
  • Conferences
  • Events
  • Partners
  • Publications
  • Resources
  • Biomarker Consortium
  • Subscribe
  • AI for Oncology
  • Biosimilars
  • Brain Cancer
  • Breast Cancer
    • HER2+ Breast Cancer
  • CAR T-Cell Therapy
  • Disparities in Cancer Care
  • Gastrointestinal Cancer
    • Pancreatic Cancer
    • Hepatocellular Carcinoma
    • Gastric Cancer
    • Colorectal Cancer
  • Genitourinary Cancers
    • Urothelial Cancer
    • Prostate Cancer
  • Global Oncology
  • Graft-vs-Host Disease
  • Gynecologic Oncology
    • Ovarian Cancer
  • Head & Neck Cancers
  • Hematologic Oncology
    • Chronic Lymphocytic Leukemia
    • Non-Hodgkin Lymphoma
    • Mantle Cell Lymphoma
    • Multiple Myeloma
    • Myeloproliferative Neoplasms
  • Immuno-Oncology
  • Lung Cancer
  • Melanoma & Skin Cancer
  • Oncology Business Management
  • Pediatric Oncology
  • Precision Medicine in Oncology®
  • Sarcomas
  • Supportive Care
Spotlight -
The OncLive Insider app is live!|
CME Opportunities
Advertisement

Practice Changing Trials in Advanced Non-Small Cell Lung Cancer

EP. 1: Treatment of Operable Locally Advanced NSCLC

February 28th 2018

EP. 2: Treatment of Unresectable Locally Advanced NSCLC

February 28th 2018

EP. 3: Surgery in the Context of Immunotherapy for Locally Advanced NSCLC

February 28th 2018

EP. 4: Potential for Use of Checkpoint Inhibitors in Early-Stage NSCLC

February 28th 2018

EP. 5: Checkpoint Inhibitors for Newly Diagnosed Stage 4 NSCLC

February 28th 2018

EP. 6: Pembrolizumab + Chemotherapy in Newly Diagnosed NSCLC

February 28th 2018

EP. 7: Immuno-Oncology Combination Therapy: Which Patients With NSCLC?

February 28th 2018

EP. 8: Quadruple Therapy for Newly Diagnosed NSCLC

February 28th 2018

EP. 9: Dual Checkpoint Inhibitor Therapy for NSCLC

February 28th 2018

EP. 10: Biomarkers for Selection of Immuno-Oncology Agents in NSCLC

February 28th 2018

EP. 11: New Standard for Treating Stage 4 EGFR+ NSCLC

February 28th 2018

EP. 12: Treatment of EGFR+ NSCLC Brain Metastases

February 28th 2018

EP. 13: Ongoing Research in EGFR+ NSCLC

February 28th 2018

EP. 14: New Standard of Care for ALK-Rearranged NSCLC

February 28th 2018

EP. 15: Sequencing Therapies for ALK-Rearranged NSCLC

February 28th 2018

EP. 16: Pearls of Wisdom for the Field of NSCLC

February 28th 2018
Advertisement
Advertisement

Trending on OncLive

1

Patient-Level Data Show Extended OS Advantage With DCVax-L vs External Controls in Glioblastoma

2

Zoldonrasib Combinations Show Compelling Antitumor Activity in RAS G12D–Mutant Metastatic PDAC

3

FDA Approves Subcutaneous Isatuximab Delivered Via On-Body Delivery System for Multiple Myeloma

4

Ensartinib Reduces Recurrence Risk After Resection in ALK-Positive NSCLC

5

Novel Antibody-Drug Conjugate Eliminates Residual Cancer Cells in Majority of Patients With B-Cell ALL

  • Advertise
  • About OncLive
  • Editorial Board
  • MJH Life Sciences brands
  • Contact Us
  • Privacy
  • Terms & Conditions
  • Do Not Sell My Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

Brand Logo
Download on Apple
Download on Google Play

© 2026 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us